These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19004729)

  • 1. [Methodological aspects on new protocols in oncology].
    Luporsi E
    Bull Cancer; 2008 Oct; 95(10):979-83. PubMed ID: 19004729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continual reassessment method: a practical design for phase 1 clinical trials in cancer.
    O'Quigley J; Pepe M; Fisher L
    Biometrics; 1990 Mar; 46(1):33-48. PubMed ID: 2350571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review: new biological insights in early clinical studies.
    Maur M; Sessa C
    Hematol Oncol; 2007 Jun; 25(2):53-7. PubMed ID: 17351979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical modifications of the continual reassessment method for phase I cancer clinical trials.
    Faries D
    J Biopharm Stat; 1994 Jul; 4(2):147-64. PubMed ID: 7951271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Design of new protocols. Role of molecular biology units?].
    Milano G
    Bull Cancer; 2008 Oct; 95(10):1003-5. PubMed ID: 19004733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Three-dose-cohort designs in cancer phase I trials.
    Huang B; Chappell R
    Stat Med; 2008 May; 27(12):2070-93. PubMed ID: 17764082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New adaptive method for phase I trials in oncology.
    Meille C; Gentet JC; Barbolosi D; André N; Doz F; Iliadis A
    Clin Pharmacol Ther; 2008 Jun; 83(6):873-81. PubMed ID: 17957185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations.
    Mandrekar SJ; Cui Y; Sargent DJ
    Stat Med; 2007 May; 26(11):2317-30. PubMed ID: 17016867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of randomized discontinuation design.
    Freidlin B; Simon R
    J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.
    Paoletti X; Baron B; Schöffski P; Fumoleau P; Lacombe D; Marreaud S; Sylvester R
    Eur J Cancer; 2006 Jul; 42(10):1362-8. PubMed ID: 16740385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New systemic therapies in oncology].
    Zaman K; Ketterer N; Vulliémoz D; Stupp R; Leyvraz S
    Rev Med Suisse; 2005 May; 1(20):1361-2, 1364-5. PubMed ID: 15991629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A non-parametric approach to the design and analysis of two-dimensional dose-finding trials.
    Ivanova A; Wang K
    Stat Med; 2004 Jun; 23(12):1861-70. PubMed ID: 15195320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes.
    Resche-Rigon M; Zohar S; Chevret S
    Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and conduct of phase II studies of targeted anticancer therapy: recommendations from the task force on methodology for the development of innovative cancer therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Eisenhauer EA; Seymour LK
    Eur J Cancer; 2008 Jan; 44(1):25-9. PubMed ID: 17845846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finding the right dose.
    Ratain MJ
    Clin Adv Hematol Oncol; 2003 Sep; 1(9):517-8, 531. PubMed ID: 16258442
    [No Abstract]   [Full Text] [Related]  

  • 18. Design issues in dose-finding Phase I trials for combinations of two agents.
    Fan SK; Venook AP; Lu Y
    J Biopharm Stat; 2009; 19(3):509-23. PubMed ID: 19384692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Applications of the partial-order continual reassessment method in the early development of treatment combinations.
    Wages NA; Dillon PM; Portell CA; Slingluff CL; Petroni GR
    Clin Trials; 2024 Jun; 21(3):331-339. PubMed ID: 38554038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer clinical trials: development and implementation.
    Vail DM
    Vet Clin North Am Small Anim Pract; 2007 Nov; 37(6):1033-57; v. PubMed ID: 17950881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.